Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks

Journal of Internal Medicine

Volumn 261, Issue 3, 2007, Pages 205-213

  Turner, M S ^b   May, D B ^a,c   Arthur, R R ^a,c   Xiong, G L ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MOSES CONE HEALTH SYSTEM   (United States)

^c CAMPBELL UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse drug reaction; Bleeding; Coagulopathy; Platelet; Selective serotonin reuptake inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; AMOXAPINE; ANTIVITAMIN K; CITALOPRAM; CORTICOSTEROID; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; MAPROTILINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PAROXETINE; SALMETEROL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

AGITATION; AKATHISIA; ANXIETY; BLEEDING; BLOOD TRANSFUSION; BULIMIA; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM ULCER; DRUG MEGADOSE; DYSTONIA; GASTROINTESTINAL HEMORRHAGE; GENERALIZED ANXIETY DISORDER; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PANIC; PARKINSONISM; POSTTRAUMATIC STRESS DISORDER; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; TARDIVE DYSKINESIA; VOMITING;

EID: 33846983203     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2006.01720.x     Document Type: Review

References (49)

1. IMS Health. National Disease and Therapeutic Index, 2006. http://www.imshealth.com.
2. IMS Health. IMS National Prescription Audit Plus, 2006. http://www.imshealth.com.
3. IMS Health. IMS National Sales Perspectives Audit, 2006. http://www.imshealth.com.
4. Kam PC, Chang GW. Selective serotonin reuptake inhibitors. Pharmacology and clinical implications in anaesthesia and critical care medicine. Anaesthesia 1997; 52: 982-8.
5. Anonymous. Fluvoxamine (package insert). Weston, FL: Apotex Corp, 2001.
6. Anonymous. Prozac (package insert). Indianapolis, IN: Eli Lilly and Co, 2003.
7. Anonymous. Paxil (package insert). Research Triangle Park, NC: GlaxoSmithKline, 2005.
8. Anonymous. Zoloft (package insert). New York, NY: Pfizer Inc., 2005.
9. Anonymous. Celexa (package insert). St Louis, MO: Forest Pharmaceuticals Inc., 2005.
10. Anonymous. Lexapro (package insert). St Louis, MO: Forest Pharmaceuticals Inc., 2005.
11. Majeroni BA, Hess A. The pharmacologic treatment of depression. J Am Board Fam Pract 1998; 11: 127-39.
12. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000; 157 (Suppl.): 1-45.
13. Goldberg RJ. Selective serotonin reuptake inhibitors: infrequent medical adverse effects. Arch Fam Med 1998; 7: 78-84.
14. Butler J, Leonard BE. The platelet serotonergic system in depression and following sertraline treatment. Int Clin Psychopharmacol 1988; 3: 343-7.
15. Serebruany VL, O'Connor CM, Krishnan RR, Hennekens CH. Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding. J Cardiovasc Pharmacol Ther 2005; 10: 163-4.
16. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med 2006; 119: 113-6.
17. 2+ mobilization in platelets. Eur J Pharmacol 1995; 288: 373-7.
18. Shen WW, Swartz CM, Calhoun JW. Is inhibition of nitric oxide synthase a mechanism for SSRI-induced bleeding? Psychosomatics 1999; 40: 268-9.
19. Markovitz JH, Shuster JL, Chitwood WS, May RS, Tolbert LC. Platelet activation in depression and effects of sertraline treatment: an open-label study. Am J Psychiatry 2000; 157: 1006-8.
20. Bakish D, Cavazzoni P, Chudzik J, Ravindran A, Hrdina PD. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biol Psychiatry 1997; 41: 184-90.
21. Alvarez JC, Gluck N, Arnulf I et al. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clin Pharmacol Ther 1999; 66: 617-24.
22. Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68: 435-42.
23. Serebruany VL, O'Connor CM, Gurbel PA. Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. Am J Cardiol 2001; 87: 1398-400.
24. Serebruany VL, Gurbel PA, Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 2001; 43: 453-62.
25. Serebruany VL, Suckow RF, Cooper TB et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. Am J Psychiatry 2005; 162: 1165-70.
26. Serebruany VL, Glassman AH, Malinin AI et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003; 108: 939-44.
27. Musselman DL, Marzec UM, Manatunga A et al. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000; 57: 875-82.
28. Serebruany VL, Glassman AH, Malinin AI et al. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail 2003; 5: 517-21.
29. Cooper TA, Valcour VG, Gibbons RB, O'Brien-Falls K. Spontaneous ecchymoses due to paroxetine administration. Am J Med 1998; 104: 197-8.
30. Calhoun JW, Calhoun DD. Prolonged bleeding time in a patient treated with sertraline. Am J Psychiatry 1996; 153: 443.
31. Leung M, Shore R. Fluvoxamine-associated bleeding. Can J Psychiatry 1996; 41: 604-5.
32. Aranth J, Lindberg C. Bleeding, a side effect of fluoxetine. Am J Psychiatry 1992; 149: 412.
33. Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ. Fluoxetine and bleeding in obsessive-compulsive disorder. Am J Psychiatry 1991; 148: 949.
34. Benazzi F. Hemorrhages during escitalopram-venlafaxine-mirtazapine combination treatment of depression. Can J Psychiatry 2005; 50: 184.
35. Lake MB, Birmaher B, Wassick S, Mathos K, Yelovich AK. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol 2000; 10: 35-8.
36. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319: 1106-9.
37. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163: 59-64.
38. Tata LJ, Fortun PJ, Hubbard RB et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 2005; 22: 175-81.
39. Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164: 2367-70.
40. van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001; 323: 655-8.
41. Movig KL, Janssen MW, de Waal MJ, Kabel PJ, Leufkens HG, Egberts AC. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. Arch Intern Med 2003; 163: 2354-8.
42. de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol 2000; 50: 43-7.
43. Layton D, Clark DW, Pearce GL, Shakir SA. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol 2001; 57: 167-76.
44. Bak S, Tsiropoulos I, Kjaersgaard JO et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 2002; 33: 1465-73.
45. Nair GV, Gurbel PA, O'Connor CM, Gattis WA, Murugesan SR, Serebruany VL. Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. Am J Cardiol 1999; 84: 321-3.
46. Jakovljevic D, Tuomilehto J. Use of selective serotonin reuptake inhibitors and the risk of stroke: is there reason for concern? Stroke 2002; 33: 1448-9.
47. Dunn NR, Pearce GL, Shakir SA. Association between SSRIs and upper gastrointestinal bleeding. SSRIs are no more likely than other drugs to cause such bleeding. BMJ 2000; 320: 1405-6.
48. Williams D, Kelly A, Feely J. Association between SSRIs and upper gastrointestinal bleeding. Coprescription of antiulcer drugs with SSRIs is fairly common. BMJ 2000; 320: 1405.
49. Po ALW. Antidepressants and upper gastrointestinal bleeding. BMJ 1999; 319: 1081-2.